Cellular Recovery & Immune Pathway

Key Research Areas

While human use is strictly prohibited, PNC-27 has been investigated in models studying:

• Selective lysis of cancer cells (pancreatic, breast, ovarian, colon, lung, leukemia)

• Synergistic cytotoxicity when combined with paclitaxel, methotrexate, or rapamycin

• In vivo tumor suppression (e.g., nude mice with pancreatic xenografts)

• Targeted peptide delivery via conjugation with nanomaterials like single-walled carbon nanotubes

• Resistance circumvention in cancer cells lacking functional p53

  Benefits Observed in Preclinical Studies

  Based on early-stage research, the following benefits have been observed in vitro and in vivo (animal models):

  • Selective Cancer Cell Necrosis: Rapidly lyses cancer cells through pore formation without harming non-cancerous tissues

  • Broad Spectrum Activity: Shown effective in solid and hematologic malignancies, including drug-resistant and p53-null cells

  • Rapid Onset: Cell lysis often occurs within hours of exposure in culture

  • Drug Potentiation: Lowers IC₅₀ values of certain chemotherapeutics in co-treatment studies

  • Tumor Reduction in Mice: Eradicates or reduces tumor volume in xenograft mouse models with minimal off-target toxicity

  • Nanoparticle Compatibility: Enhances tumor targeting when paired with drug delivery systems

Research Use Only:

PNC-27 is intended strictly for in vitro testing and laboratory experimentation. It’s not intended for human or animal medical use. It’s not a drug, food, or cosmetic and should not be misbranded, misused, or mislabeled as such.